|

Autologous CAR123 T lymphocytes Clinical Trials

1 actively recruiting trial

Also known as: Autologous T-cell Therapy, CAR123 T Cells, CART123

Pipeline

Early 1: 1

Top Sponsors

  • Institute of Hematology and Blood Transfusion, Czech Republic1

Indications

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)1
  • Leukemia, Myeloid, Acute(AML)1
  • Myelodysplastic Syndromes (MDS)1
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma1
  • Cancer1

Other1 trial

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.